Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 4/20 | 0.68 |
| ▸ | CCND1 | P24385 | 4/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.65 |
| ▸ | LMNA | P02545 | 1/20 | 0.64 |
| ▸ | TERT | O14746 | 2/20 | 0.56 |
| ▸ | DRD2 | P14416 | 1/20 | 0.56 |
| ▸ | DRD4 | P21917 | 1/20 | 0.56 |
| ▸ | DRD3 | P35462 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | FABP4 | P15090 | 1/20 | 0.54 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.54 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.54 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | KMO | O15229 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29560163 | 1.00 | CDK4 (0.68) | CDK4CCND1KMT2ALMNATERT | |
| SCHEMBL1269116 | 0.95 | CDK4 (0.71) | CDK4CCND1KMT2ALMNATERT | |
| SCHEMBL30582936 | 0.94 | CDK4 (0.72) | CDK4CCND1KMT2ALMNATERT | |
| SCHEMBL19783673 | 0.94 | CDK4 (0.72) | CDK4CCND1KMT2ALMNATERT | |
| SCHEMBL526317 | 0.90 | LMNA (0.73) | CDK4CCND1KMT2ALMNATERT | |
| SCHEMBL29684637 | 0.90 | LMNA (0.73) | CDK4CCND1KMT2ALMNATERT | |
| SCHEMBL22610155 | 0.81 | CDK4 (0.60) | CDK4CCND1KMT2ALMNAMAPK1 | |
| SCHEMBL5051883 | 0.81 | LMNA (0.61) | CDK4CCND1KMT2ALMNADRD2 | |
| SCHEMBL31370177 | 0.80 | MAPK1 (0.62) | CDK4CCND1KMT2ALMNAMAPK1 | |
| SCHEMBL27587769 | 0.80 | ALOX5 (0.50) | CDK4CCND1KMO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109369500-B | Separation method of 3-indolebutyric acid and 1-indolebutyric acid | 浙江大鹏药业股份有限公司 | 2020-04-24 | — | — | CN | claimed |
| CN-109369500-A | A kind of separation method of 3- indolebutyric acid and 1- indolebutyric acid | 台州市大鹏药业有限公司 | 2019-02-22 | — | — | CN | claimed |
| EP-2509424-A1 | NOVEL OXADIAZOLE COMPOUNDS | Abbott Laboratories (US) | 2012-10-17 | — | — | EP | claimed |
| WO-2011071570-A1 | NOVEL OXADIAZOLE COMPOUNDS | ABBOTT LABORATORIES (US) | 2011-06-16 | — | — | WO | claimed |
| EP-0715627-A1 | INDOLE DERIVATIVES AS THROMBOXANE A2 ANTAGONISTS | Pfizer Limited (GB) | 1996-06-12 | — | — | EP | claimed |
| CN-117958143-A | Preparation and application of culture medium for improving rooting property of trichosanthes kirilowii Maxim tissue culture seedlings | 安徽中医药大学 | 2024-05-03 | — | — | CN | disclosed |
| CN-114208516-B | Root section propagation method of arrow | 四川省内江市农业科学院 | 2023-07-14 | — | — | CN | disclosed |
| US-20200345858-A1 | COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF ERGOT ALKALOID TOXICITY | LINDA LIGHT | 2020-11-05 | — | — | US | disclosed |
| EP-3700523-A1 | COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF ERGOT ALKALOID TOXICITY | Light, Linda (US) | 2020-09-02 | — | — | EP | disclosed |
| CN-109369500-B | Separation method of 3-indolebutyric acid and 1-indolebutyric acid | 浙江大鹏药业股份有限公司 | 2020-04-24 | — | — | CN | disclosed |
| CN-109369500-B | Separation method of 3-indolebutyric acid and 1-indolebutyric acid | 浙江大鹏药业股份有限公司 | 2020-04-24 | — | — | CN | disclosed |
| CN-109369500-B | Separation method of 3-indolebutyric acid and 1-indolebutyric acid | 浙江大鹏药业股份有限公司 | 2020-04-24 | — | — | CN | disclosed |
| CN-109369500-A | A kind of separation method of 3- indolebutyric acid and 1- indolebutyric acid | 台州市大鹏药业有限公司 | 2019-02-22 | — | — | CN | disclosed |
| CN-109369500-A | A kind of separation method of 3- indolebutyric acid and 1- indolebutyric acid | 台州市大鹏药业有限公司 | 2019-02-22 | — | — | CN | disclosed |
| CN-109369500-A | A kind of separation method of 3- indolebutyric acid and 1- indolebutyric acid | 台州市大鹏药业有限公司 | 2019-02-22 | — | — | CN | disclosed |
| EP-2997028-A1 | AZA-OXO-INDOLES FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS INFECTION | F.HOFFMANN-LA ROCHE AG (CH) | 2016-03-23 | — | — | EP | disclosed |
| WO-2014184163-A1 | AZA-OXO-INDOLES FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS INFECTION | F. HOFFMANN-LA ROCHE AG (CH) | 2014-11-20 | — | — | WO | disclosed |
| EP-0598750-A1 | INDOLES | Pfizer Limited (GB) | 1994-06-01 | — | — | EP | disclosed |
| US-4273782-A | FOR USE IN CARDIOVASCULAR DISORDERS AND COMPLICATIONS OF DIABETES | PFIZER INC. (US) | 1981-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200345858-A1 | COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF ERGOT ALKALOID TOXICITY | FH, CRH, HYPK | CDK4 4470/4885CCND1 3906/4885KMT2A 2194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.